Keywords: Celgene, Abraxane, Gemcitabine, Ph III, Pancreatic cancer, Survival

Celgene's Abraxane plus gemcitabine extends survival in pancreatic cancer patients

Article | 23 January 2013

Print This

US biotech firm Celgene Corp (Nasdaq: CELG) says that its Phase III clinical trial of Abraxane (nab-paclitaxel) in combination with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in